Transaction #24674 · Form 4 · 0001104659-26-116966
CITY THERAPEUTICS, INC. · Purchase · Common Stock
CITY THERAPEUTICS, INC. · Transacted October 19, 2026 · Filed October 19, 2026
What does this filing report?
An SEC Form 4 filing for CITY THERAPEUTICS, INC. records a purchase involving Common Stock on October 19, 2026. The reported quantity was 170,000. The filing date is October 19, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- CITY THERAPEUTICS, INC.
- Company CIK
- 0002143850
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 170,000
- Reported price
- 18
- Reference value
- 3,060,000
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 13,692,507
- Ownership description
- By ARCH Venture Fund XII, L.P.
- SEC acceptance time
- Oct 19, 2026, 5:38 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- CRANDELL KEITH ↗
10% owner
CIK 0001219039
- GILLIS STEVEN ↗
10% owner
CIK 0001229592
- Burow Kristina ↗
10% owner
CIK 0001569248
- ARCH Venture Fund XII, L.P. ↗
10% owner
CIK 0001906837
- ARCH Venture Partners XII, LLC ↗
10% owner
CIK 0001979548
- ARCH Venture Partners XII, L.P. ↗
10% owner
CIK 0001979765
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Each share of Series Seed convertible preferred stock, Series A convertible preferred stock and Series B convertible preferred stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-to-1.0983 basis at the option of the holder, and automatically converted into Common Stock upon the closing of the Issuer's initial public offering on October 19, 2026 without payment of consideration. The Preferred Stock had no expiration date.
- F2
- Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Mr. Nelsen serves on the board of directors of the Issuer and is filing his own Form 4 separately.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.